<DOC>
	<DOCNO>NCT01825330</DOCNO>
	<brief_summary>The study test effect NeuroAD Alzheimer patient ' cognitive function . The NeuroAD use non-invasive stimulation magnetic cognitive training .</brief_summary>
	<brief_title>Effect NeuroAD Cognitive Function Alzheimer Patients</brief_title>
	<detailed_description>The NeuroAD system combine system Transcranial Magnetic Stimulation cognitive training non-invasive therapeutic system improvement Alzheimer patient ' cognitive function . A potential participant undergo screening procedure confirm eligibility participate study , follow randomization procedure one study group - treatment sham ( placebo ) Patient attend clinic 5 time week 6 week , approximately hour every day treatment/sham . The patient require return clinic follow-up . Up 150 patient enrol 10 clinical site US Israel .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Male female age 6090 year 2 . Patients diagnose mild moderate stage Alzheimer 's Disease , accord DSMIV criterion . 3 . MMSE score 18 26 4 . ADASCog 17 5 . Physical clearance study participation evaluate clinician . 6 . Spouse , family member professional caregiver agree capable take care responsible participation patient study ( answer question regard patient 's condition assume responsibility medication ) 7 . Agreement participate approximately 14 week study . 8 . Normal nearnormal vision hear correction need ( e.g . corrective lens , hear aid ) . 9 . Fluent English Hebrew 10 . Minimum 8th grade education 11 . If medicate AD , use cholinesterase inhibitor , memantine Ginkobiloba least 3 month stable dose least 60 day prior screen . 1 . CDR 0 , 0.5 3 2 . Severe agitation 3 . Mental retardation 4 . Patient lack capacity consent study participation 5 . Unstable medical condition 6 . Use benzodiazepine barbiturates 2 week prior screen 7 . Pharmacological immunosuppression 8 . Participation clinical trial investigational agent within 6 month prior study enrollment 9 . History Epileptic Seizures Epilepsy 10 . Contraindication perform MRI scan 11 . Contraindication receive TMS treatment accord TMS questionnaire 12 . Pregnant woman woman ability become pregnant unless acceptable method contraception study . 13 . Patients depression , bipolar disorder psychotic disorder neurological psychiatric condition ( whether past ) , Investigator find interfere study 14 . Alcoholism drug addiction define DSMIV within last 5 year ( addict one year remission le 3 year ) severe sleep deprivation 15 . Patients metal implant head , ( i.e . cochlear implant , implant brain stimulators , aneurysm clip ) exception metal implant mouth 16 . Patients personal history either clinically define medical disorder ( investigator find interfere study ) clinically define neurological/psychiatric disorder ( AD ) , include ( limited ) : epilepsy , stroke , brain lesion , substance abuse , vitamin B12 deficiency , abnormal thyroid function , cerebrovascular condition , neurodegenerative disease , head trauma , multiple sclerosis ; personal history previous neurosurgery head trauma result loss consciousness . 17 . Patients sign symptom increase intracranial pressure , determine neurological exam . 18 . Cardiac pacemaker 19 . Implanted medication pump 20 . Intracardiac line 21 . Significant heart disease 22 . Currently take medication low seizure threshold . 23 . Patients TMS Motor Threshold find . 24 . Patient underwent TMS treatment past .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Alzheimer 's</keyword>
	<keyword>TMS</keyword>
	<keyword>Cognitive Training</keyword>
	<keyword>NeuroAD</keyword>
</DOC>